Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

58.44
-1.5600-2.60%
Post-market: 58.28-0.1647-0.28%19:46 EDT
Volume:2.08M
Turnover:122.59M
Market Cap:11.29B
PE:154.20
High:60.16
Open:59.81
Low:58.39
Close:60.00
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.11
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.79
PE(LYR):32.47

Loading ...

Biomarin Pharmaceutical Inc - Plans FDA Supplemental Nda Submission for Voxzogo in Q3 2026

THOMSON REUTERS
·
May 21

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 20

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
May 20

BioMarin price target lowered to $80 from $85 at BofA

TIPRANKS
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Simply Wall St.
·
May 19

BioMarin initiated with a Buy at Citi

TIPRANKS
·
May 19

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 18

BUZZ-BioMarin falls after genetic disease therapy shows mixed results in study

Reuters
·
May 18

BioMarin price target lowered to $50 from $55 at H.C. Wainwright

TIPRANKS
·
May 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $50 From $55

THOMSON REUTERS
·
May 18

BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live
·
May 18

Biomarin Pharmaceutical Shares Down 1% After Genetic Disease Therapy Shows Mixed Results in Late-Stage Study

THOMSON REUTERS
·
May 18

BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial

TIPRANKS
·
May 18

BioMarin's genetic disease therapy shows mixed results in late-stage study

Reuters
·
May 18

Biomarin Pharmaceutical Inc - Energy 3 Study Meets 1 of 2 Co-Primary Endpoints in Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Generally Well-Tolerated With No New Safety Signals Reported

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Improvement in Radiagraphic Global Impression of Change Scores in Energy 3 Study

THOMSON REUTERS
·
May 18